May 2013 Issue of MMM
MAY 2013 ISSUE
When Ian Talmage, Bayer HealthCare's SVP, global marketing, was faced with a cancer diagnosis, he found that other patients had more information to offer him ...
Click the above link to access the complete Digital Edition of the May 2013 issue, with all text, charts and pictures.
What's that image fading from view? Pharma just sped by one precipice, losing $30 billion in brand revenue to the patent cliff. But another scary ...
Co-pay cards and loyalty/CRM programs are a hot topic. As Larry Dobrow finds, a big disconnect still divides the stakeholders in this field
When it comes to conveying the changes that have transformed pharma, college degree programs can fall short. The answer may be faculty with pharma marketing ...
The 2013 panel features a variety of esteemed leaders, thinkers and experts representing a range of disciplines. Their hard work will determine which agencies win ...
Mike Kaufman, Executive sponsor, Women's Initiative Network, Cardinal Health
Noah Pines on the roll-out of Pfizer's new RA pill Xeljanz, a biologic maker's response, and how the upstart may prompt a move away from ...
For all the advances in technology and methodology, qualitative research cannot shed its history like its quant sibling
CD47 is one story that the media may have gotten right.
The White House has released its proposed budget for the 2014 fiscal year, and while it gives a modest boost to Health and Human Services, ...
A recent study by Booz & Co, signals what it takes to convert emerging markets from potential revenue sources into financially sustaining markets
Sales jobs aren't vaporizing, Accenture's global director of life sciences Craig Roberston told MM&M—rather, they're being reconfigured, and in some cases, relocated.
News on Bristol-Myers Squibb, AstraZeneca and Accenture
Med Ed Report
For Pfizer and GlaxoSmithKline, the effects of expiring patents on blockbuster drugs took their toll on payments to US doctors last year.
It takes nearly two years for results from the average clinical trial to be published, across all funders, according to a new study.
A whistleblower says Cephalon used CME, "bogus 'market research surveys' and Advisory Board meetings" to disseminate an off-label message about Treanda to prescribers.
News on Pfizer, Novartis, Teva, SternScientific, Roche and the PharmedOut Conference
Elsevier is replacing its OncologyStat portal with a multidisciplinary news and research aggregator called PracticeUpdate
Wiley announced in March that it will enter 2014 with at least 66 new titles under its umbrella
News on the American Diabetes Association, MedCity News, UBM Medica and the American College of Physicians
Pharmas are restructuring to implement digital marketing initiatives—for instance, using social media to build brands or engage audiences. As they partner, how should agencies help ...
Google's latest YouTube update aims to make its Channels more social, and even as the company has given its pharma clients an extra month to ...
WebMD is getting personal. That's the upshot of the portal's latest venture, an alliance with QualcommLife.
News on Sanofi, the MediSafe Project and Vital Art and Science
Sanofi Pasteur scored a pharma first this past winter by offering "Shazam" technology as a way for viewers to interact with TV commercials for its ...
The "Take This!" campaign for Novartis' Gilenya is remarkable because of its high energy and attitude
Pfizer is partnering with YMCA of the USA for a wellness campaign targeting boomers
Athenahealth has wasted little time in putting its mark on Epocrates
Fiscal concerns are paramount in the rise of Big Data within healthcare, according to a recent McKinsey analysis, but clinical trends also play a role
Two of the pharma social media world's biggest names made career changes in March
Weber Shandwick is launching a high-science shop, dubbed Element Scientific Communications
News on Saatchi & Saatchi Wellness, Omincom, Ogilvy CommonHealth, WholeView and ApotheCom Group
Appendages of the HHS secretary's apron strings, FDA commissioners must toe the "party line"
FDA drug safety officials say that an influx of numerous bleeding reports associated with Boehringer Ingelheim's blood thinner Pradaxa (dabigatran) is a case of "stimulated ...
Organization including the Pew Charitable Trusts are voicing basic suppor for FDA's efforts to develop an alternative approval pathway for certain drugs
The balance of power is shifting to put marketing closer to the "editorial center" of the commercial model
Positive Deviance involves finding out what works and replicating it throughout an organization
If pharma advertising can stimulate gut instincts—with contrasts like before/after, risky/safe, with/without—it will be more effective
Tim Pantello, Managing Director, Digitas Health
At Work With
Kathy Delaney, Global chief creative officer, Saatchi & Saatchi Wellness
Manufacturer, agency and consultancy promotions and hires
FDA cannot rely solely on the label or the current standard for drug approvals
Skill Sets (advertising section)
What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.